Effects of 4-aminopyridine in experimental CNS demyelination.
We studied the effect of systemically administered 4-aminopyridine in a model of CNS demyelination. In five rats with demyelination, slowed conduction velocity through the lesion was partially reversed at dose levels of 5.6 to 7.2 mg/kg. All rats developed convulsion at this dosage, and impaired conduction of high-frequency impulses was unchanged. These findings suggest certain limitations of 4-aminopyridine as a therapeutic agent.
Kaji
R
R
Department of Neurology, University of Pennsylvania, Philadelphia.
Sumner
A J
AJ
D015761:4-Aminopyridine; D000631:Aminopyridines / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D003711:Demyelinating Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D008297:Male; D009431:Neural Conduction / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000139:chemically induced
D000631:Aminopyridines; D015761:4-Aminopyridine